Search results for " Sars-CoV-2"

showing 10 items of 208 documents

Reduced Self-Awareness Following a Combined Polar and Paramedian Bilateral Thalamic Infarction. A Possible Relationship With SARS-CoV-2 Risk of Conta…

2020

Reduced self-awareness is a well-known phenomenon investigated in patients with vascular disease; however, its impact on neuropsychological functions remains to be clarified. Importantly, selective vascular lesions provide an opportunity to investigate the key neuropsychological features of reduced self-awareness in neurocognitive disorders. Because of its rarity, we present an unusual case of a woman affected by a combined polar and paramedian bilateral thalamic infarction. The patient underwent an extensive neuropsychological evaluation to assess cognitive, behavioral, and functional domains, with a focus on executive functions. She was assessed clinically in the acute phase and after 6 m…

Pediatricsmedicine.medical_specialtylcsh:BF1-990case study; executive functions; polar and paramedian thalamic infarction; reduced self-awareness; SARS-CoV-2reduced self-awarenessCase Report050105 experimental psychologycase study03 medical and health sciences0302 clinical medicinepolar and paramedian thalamic infarctionmedicinePsychology0501 psychology and cognitive sciencesApathyStrokeGeneral PsychologyDepression (differential diagnoses)SARS-CoV-2Vascular disease05 social sciencesNeuropsychologyexecutive functionsmedicine.diseaseExecutive functionslcsh:Psychologymedicine.symptomPsychologyNeurocognitive030217 neurology & neurosurgeryExecutive dysfunctionFrontiers in Psychology
researchProduct

Deciphering the Potential of Pre and Pro-Vitamin D of Mushrooms against Mpro and PLpro Proteases of COVID-19: An In Silico Approach

2022

Vitamin D’s role in combating the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus causing COVID-19, has been established in unveiling viable inhibitors of COVID-19. The current study investigated the role of pre and pro-vitamin D bioactives from edible mushrooms against Mpro and PLpro proteases of SARS-CoV-2 by computational experiments. The bioactives of mushrooms, specifically ergosterol (provitamin D2), 7-dehydrocholesterol (provitamin-D3), 22,23-dihydroergocalciferol (provitamin-D4), cholecalciferol (vitamin-D3), and ergocalciferol (vitamin D2) were screened against Mpro and PLpro. Molecular docking analyses of the generated bioactive protease complexes unr…

Pharmaceutical Scienceedible mushroomsMolecular Dynamics SimulationViral Nonstructural ProteinsAnalytical Chemistrypro-vitamin-DErgosterolDrug DiscoveryEndopeptidasespre-vitamin-DHumansProtease InhibitorsPhysical and Theoretical ChemistryVitamin DSARS-CoV-2Organic ChemistryProvitaminsin-silico studiesSettore CHIM/08 - Chimica FarmaceuticaCOVID-19 Drug TreatmentMolecular Docking SimulationChemistry (miscellaneous)Molecular MedicineAgaricalesedible mushrooms; SARS-CoV-2; pre-vitamin-D; pro-vitamin-D; in-silico studiesPeptide HydrolasesMolecules; Volume 27; Issue 17; Pages: 5620
researchProduct

Diabetes and COVID-19: A Tale of 2 Pandemics.

2021

Abstract: Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact of dapagliflozin on COVID-19 and its complications.

Pharmacology2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)diabetesbusiness.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19Review Articledapagliflozinmedicine.diseaseVirologyDARE-19Diabetes mellitusPandemicmedicineDiabetes MellitusHumansSGLT2iCardiology and Cardiovascular MedicinebusinessPandemicsHumans Pandemics SARS-CoV-2 COVID-19 Diabetes MellitusJournal of cardiovascular pharmacology
researchProduct

Evaluation of the Oral Microcirculation in Patients Undergoing Anti COVID-19 Vaccination: A Preliminary Study

2022

Videocapillaroscopy allows the study of both the morphological and architectural structure of the microcirculation and its hemodynamic conditions; these parameters are directly involved in autoimmune and/or inflammatory pathologies. The purpose of this research, based on capillaroscopy, is to establish whether a patient who receives an anti-COVID 19 vaccine has any changes in their oral microcirculation. A complete capillaroscopic mapping of the oral cavity of the subjects examined was made; the investigated mucosa sites were the following: cheek, labial, chewing-gingival and back of the tongue. This study showed an increase in capillary density from the comparison between the mean labial c…

PharmacologyInfectious DiseasesCOVID 19 vaccineSARS-CoV-2 infectionDrug DiscoveryImmunologycapillaroscopymicrocirculationPharmacology (medical)COVID 19 vaccine; SARS-CoV-2 infection; capillaroscopy; microcirculation
researchProduct

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and…

2022

Background: Research shows that in most people, two-dose vaccination helps to shape the humoral response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Further studies are required to learn about the vaccine’s effectiveness after boosting. Methods: We conducted a prospective study among 103 healthcare workers (HCWs) from a regional multi-specialty hospital vaccinated with three doses of the BNT162b2 vaccine. We compared their immunoglobulin G (IgG) titers 14 days after the second dose with those 21 days after the booster. We also compared their anthropometric and body composition parameters with IgG concentrations at the same time points. Results: Twenty-one days aft…

PharmacologyInfectious DiseasesDrug DiscoveryImmunologyPharmacology (medical)IgG antibody; SARS-CoV-2; COVID-19; healthcare workers; humoral response; COVID-19 vaccine; BNT162b2 vaccine; immunization; body composition; boosterVaccines; Volume 10; Issue 10; Pages: 1638
researchProduct

Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System

2022

To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination …

PharmacologySARS-CoV-2Immunologyadverse reactionactive surveillance systemadverse reaction; vaccine; coronavirus; SARS-CoV-2; m-RNA; female; young people; active surveillance systemyoung peoplecoronavirufemaleInfectious DiseasesvaccineDrug DiscoveryPharmacology (medical)m-RNAVaccines
researchProduct

Knowledge, Attitudes, Perceptions and Vaccination Acceptance/Hesitancy among the Community Pharmacists of Palermo’s Province, Italy: From Influenza t…

2022

In Italy, following the start of the SARS-CoV-2 vaccination campaign, community pharmacies (CPs) were recruited on a voluntary basis in order to administer COVID-19 vaccines as part of their activities. The aim of the present study was to investigate the knowledge, attitudes, and practices regarding SARS-CoV-2 infection prevention, and vaccine acceptance/hesitancy towards COVID-19 and influenza vaccinations among the community pharmacists operating in the Palermo Province. A cross-sectional study was conducted, with two different questionnaires administered before and after the conduction of the vaccination campaign against SARS-CoV-2 at the COVID-19 vaccination center of the Palermo Univer…

Pharmacologycommunity pharmacistInfectious DiseasesCOVID-19 vaccinationSARS-CoV-2 infectionhealthcare professionalDrug DiscoveryImmunologyPharmacology (medical)influenza vaccinationvaccine hesitancy.influenza vaccination; COVID-19 vaccination; community pharmacists; KAPs; vaccine hesitancy; healthcare professionals; SARS-CoV-2 infectionVaccines
researchProduct

A potential host and virus targeting tool against COVID-19: Chemical characterization, antiviral, cytoprotective, antioxidant, respiratory smooth mus…

2023

COronaVIrus Disease 2019 (COVID-19) is a newly emerging infectious disease that spread across the world, caused by the novel coronavirus Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2). Despite the advancements in science that led to the creation of the vaccine, there is still an urgent need for new antiviral drugs effective against SARS-CoV-2. This study aimed to investigate the antiviral effect of Paulownia tomentosa Steud extract against SARS-CoV-2 and to evaluate its antioxidant properties, including respiratory smooth muscle relaxant effects. Our results showed that P. tomentosa extract can inhibit viral replication by directly interacting with both the 3-chymotrypsin-like…

Pharmacologysars-cov-2covid-19antioxydantcovid-19; paulownia tomentosa steud extract; antiviral; antioxydant; phytocomplex; sars-cov-2paulownia tomentosa steud extractGeneral MedicinephytocomplexantiviralBiomedicine & Pharmacotherapy
researchProduct

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

2020

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COV…

Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Index
researchProduct

Helmet continuous positive airway pressure and prone positioning: A proposal for an early management of COVID-19 patients

2020

In late December 2019, clusters of patients with interstitial pneumonia of unknown cause were reported by some local health facilities in Wuhan (China). The Chinese Centre for Disease Control conducted an epidemiologic and etiologic investigation, leading to the identification of a novel coronavirus (SARS-CoV-2).1, 2 On March 11th, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) a pandemic. In the area of Wuhan, COVID-19 mainly affected male patients (around 60%), with a median age of about 50 years; 40% of patients developed Acute Respiratory Distress Syndrome (ARDS) 5% requiring intensive care. The mortality rate was around 2%.3, 4 However, Grasselli …

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.medical_treatmentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralcoronavirusArticlePatient PositioningPositive-Pressure RespirationBetacoronavirusPandemicmedicineHumansContinuous positive airway pressurePositive-Pressure RespirationHypoxiaLung CompliancePandemicslcsh:RC705-779Respiratory Distress SyndromeContinuous Positive Airway PressurebiologySARS-CoV-2business.industryhelmetCOVID-19lcsh:Diseases of the respiratory systembiology.organism_classificationProne positionVasoconstrictionprone positionEmergency medicineHead Protective DevicesCoronavirus InfectionsRespiratory InsufficiencybusinessBetacoronavirusCPCP COVID-19 SARS-CoV-2
researchProduct